Year: 2023

Conference Call Scheduled for 8:30 a.m. Eastern Time WEST PALM BEACH, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) — AMG (NYSE: AMG) will report financial and operating results for the third quarter ended September 30, 2023 on Monday, November 6, 2023. A conference call will be held at 8:30 a.m. Eastern time on the same day. In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, and Thomas M. Wojcik, Chief Financial Officer, will host the session. Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins. The conference call will also be available for replay beginning approximately one hour...

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approvedFLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults. VOQUEZNA treatment regimens contain antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive...

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) — INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2023 on Thursday, November 9, 2023 after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE’s Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the “Investor Relations” section of the Company’s website at least 15 minutes prior to the start of the call to register and download any necessary audio...

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November:Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Monday, November 6, 2023 at 9:50 a.m. ET in New York, NY. Members of management will also be available for one-on-one meetings. Stifel 2023 Healthcare Conference: Gwendolyn Binder, Ph.D., President of Science and Technology, will participate in a fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York, NY. Members...

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below: Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference Format: Fireside Chat Date and Time: Monday, November 6, 2023, 9:50 – 10:20 AM ESTWebcast: https://guggenheim.metameetings.net 6th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside Chat Date and Time: Thursday, November 30, 2023, 10:50 – 11:10 AM ESTWebcast: https://wsw.com/webcast/evercore39/vera A replay of the presentations will be available...

NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that it will release financial results for the third quarter ended September 30, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, November 13, 2023. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 381129Webcast: https://www.webcaster4.com/Webcast/Page/2879/49364 About iCADiCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier...

The Company is fully-permitted for advanced exploration drilling and expects to begin drilling the first week of November, 2023 CALGARY, Alberta, Oct. 30, 2023 (GLOBE NEWSWIRE) — Pan American Energy Corp. (CSE: PNRG | OTC: PAANF | FRA: SS60) (“Pan American” or the “Company“) is pleased to announce that it has selected Full Force Diamond Drilling Ltd. (“Full Force”) as the drilling contractor for the fully-permitted advanced exploration drilling program at the Big Mack Lithium Project, the Company’s hard rock pegmatite lithium prospective property located approximately 80 kilometers north of the town of Kenora, Ontario (the “Property”). Full Force was selected after a rigorous and competitive analysis and qualification process supported by the Company’s project partner, Magabra Resources Corp. (“Magabra”), and...

Management and Key Opinion Leader to Highlight Recent Data on NE3017 Presented at CTAD Conference CARSON CITY, Nev., Oct. 30, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that the Company’s management will host a conference call and webcast on Wednesday, November 1 2023 at 8:00 AM Eastern Time. BioVie’s President and CEO Cuong Do, Chief Medical Officer Dr. Joseph Palumbo, and Dr. Steven Arnold of the Harvard Medical School will review recent data on NE3017 presented at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. Registration details are as follows:Date November 1, 2023Time 8:00 AM Eastern TimeConference...

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform...

Priority review granted with PDUFA target action date of April 30, 2024 BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024. The FDA is not currently planning to hold an advisory committee meeting to discuss the application. pLGG is the most common brain tumor diagnosed in children,...